Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Teresa Helsten

    TitleAssociate Clinical Professor
    SchoolUniversity of California, San Diego
    DepartmentMedicine
    Address9500 Gilman Drive #0987
    CA La Jolla 92093
    Phone858-657-6746

       Overview 
       Overview
      Research Interests
      Dr. Helsten focuses first and foremost on providing excellent care for breast cancer patients. She provides neoadjuvant, adjuvant, and metastatic treatments, including endocrine therapy, chemotherapy, and targeted therapies. She actively enrolls patients to clinical trials.

      Dr. Helsten’s research is primarily focused on clinical trials chosen to bring the most cutting edge care to her patients. She runs several clinical trials and enrolls patients to these and cooperative group and investigator initiated trials at UCSD. She is a coinvestigator of the groundbreaking I-SPY 2 study (www.ispy2.org). She is actively engaged in the design and implementation of translational research projects in breast cancer. FGFR inhibitors are of particular interest.

      Education and Training
      BS - Chemistry, Massachusetts Institute of Technology - 1990
      MD - University of California, Davis - 1998
      Resident - Harbor-UCLA Medical Center - 1998-2001
      Chief Resident - Harbor-UCLA Medical Center - 2001-2002
      Oncology Fellowship - UC San Diego Medical Center - 2002-2005

       Interests
      Medical oncology, Breast cancer, Clinical Trials, FGFR, Fibroblast growth factor, Fibroblast growth factor receptor

       ORNG Applications 
       Websites

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker BA, Helsten T, Kurzrock R. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Cell Cycle. 2015 May 7; 1-8.
        View in: PubMed
      2. Scott BJ, van Vugt VA, Rush T, Brown T, Chen CC, Carter BS, Schwab R, Fanta P, Helsten T, Bazhenova L, Parker B, Pingle S, Saria MG, Brown BD, Piccioni DE, Kesari S. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. J Neurooncol. 2014 Sep; 119(2):361-8.
        View in: PubMed
      3. Costantini C, Ale-Ali A, Helsten T. Sleep aid prescribing practices during neoadjuvant or adjuvant chemotherapy for breast cancer. J Palliat Med. 2011 May; 14(5):563-6.
        View in: PubMed
      4. Helsten TL, Bunch TA, Kato H, Yamanouchi J, Choi SH, Jannuzi AL, Féral CC, Ginsberg MH, Brower DL, Shattil SJ. Differences in regulation of Drosophila and vertebrate integrin affinity by talin. Mol Biol Cell. 2008 Aug; 19(8):3589-98.
        View in: PubMed
      5. Bunch TA, Helsten TL, Kendall TL, Shirahatti N, Mahadevan D, Shattil SJ, Brower DL. Amino acid changes in Drosophila alphaPS2betaPS integrins that affect ligand affinity. J Biol Chem. 2006 Feb 24; 281(8):5050-7.
        View in: PubMed
      Back to TOP